JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Times cited: 57
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Times cited: 49
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Proceedings of the National Academy of Sciences of the United States of America.
Times cited: 91